Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529987 | 0.81 | RAB9A (0.60) | RAB9ATDP1MAPK10ALDH1A1ROCK2 | |
| SCHEMBL29980732 | 0.78 | RAB9A (0.58) | RAB9ATDP1ALDH1A1GAAMAPT | |
| SCHEMBL1723847 | 0.78 | RAB9A (0.58) | RAB9ATDP1ALDH1A1GAAMAPT | |
| SCHEMBL742272 | 0.77 | RAB9A (0.75) | RAB9ATDP1ALDH1A1GAAMAPT | |
| Methane SCHEMBL25344317 | 0.77 | RAB9A (0.56) | RAB9ATDP1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL16797856 | 0.77 | RAB9A (0.56) | RAB9ATDP1ALDH1A1GAAMAPT | |
| SCHEMBL6455377 | 0.76 | RAB9A (0.74) | RAB9ATDP1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL6831509 | 0.76 | RAB9A (0.73) | RAB9ATDP1ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL6831889 | 0.75 | RAB9A (0.59) | RAB9ATDP1ALDH1A1GAAMAPT | |
| SCHEMBL6120085 | 0.75 | RAB9A (0.67) | RAB9ATDP1ALDH1A1MAPTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | RAB9A 902/4885TDP1 1807/4885MAPK9 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.